|
Q1 2025
|
13 |
288,452 |
BBIO, I9SA.HA, SNDX, BCAX
|
13F-HR
|
5/13/2025 |
000176672125000003 |
|
Q4 2024
|
15 |
281,834 |
BBIO, I9SA.HA, SNDX, GLUE
|
13F-HR
|
2/12/2025 |
000176672125000001 |
|
Q3 2024
|
16 |
261,072 |
BBIO, I9SA.HA, SNDX, Bicara Therapeutics Inc. (BCAX)
|
13F-HR
|
11/13/2024 |
000204258624000002 |
|
Q2 2024
|
15 |
231,052 |
BBIO, SNDX, I9SA.HA, ELEV
|
13F-HR
|
8/8/2024 |
000176672124000004 |
|
Q1 2024
|
16 |
295,497 |
BBIO, SNDX, I9SA.HA, ELEV
|
13F-HR
|
5/14/2024 |
000176672124000003 |
|
Q4 2023
|
16 |
335,237 |
BBIO, I9SA.HA, SNDX, BMEA
|
13F-HR
|
2/7/2024 |
000176672124000002 |
|
Q3 2023
|
17 |
242,681 |
BBIO, I9SA.HA, SNDX, BMEA
|
13F-HR
|
11/13/2023 |
000176672123000004 |
|
Q2 2023
|
16 |
204,132 |
BBIO, I9SA.HA, SNDX, BMEA
|
13F-HR
|
8/11/2023 |
000176672123000003 |
|
Q1 2023
|
16 |
207,812 |
BBIO, BMEA, I9SA.HA, SNDX
|
13F-HR
|
5/9/2023 |
000176672123000002 |
|
Q4 2022
|
16 |
151,470 |
BBIO, I9SA.HA, SNDX, GLUE
|
13F-HR
|
2/9/2023 |
000176672123000001 |
|
Q3 2022
|
17 |
150,591 |
BBIO, SNDX, I9SA.HA, GLUE
|
13F-HR
|
11/3/2022 |
000176672122000007 |
|
Q2 2022
|
19 |
140,160 |
BBIO, SNDX, GLUE, BMEA
|
13F-HR
|
8/10/2022 |
000176672122000006 |
|
Q1 2022
|
21 |
185,304 |
BBIO, GLUE, SNDX, HRMY
|
13F-HR
|
5/10/2022 |
000176672122000005 |
|
Q4 2021
|
21 |
283,454 |
BBIO, GLUE, SNDX, NUVB
|
13F-HR
|
2/18/2022 |
000176672122000002 |
|
Q3 2021
|
21 |
501,479 |
BBIO, GLUE, NUVB, HRMY
|
13F-HR
|
11/12/2021 |
000176672121000006 |
|
Q2 2021
|
21 |
624,578 |
BBIO, ELEV, GLUE, HRMY
|
13F-HR
|
8/6/2021 |
000176672121000005 |
|
Q1 2021
|
15 |
555,604 |
BBIO, HRMY, NUVB, SNDX
|
13F-HR
|
5/14/2021 |
000176672121000004 |
|
Q4 2020
|
16 |
582,316 |
BBIO, Eidos Therapeutics, Inc. (EIDIX), HRMY, SPRB
|
RESTATEMENT
|
2/5/2021 |
000176672121000003 |
|
Q3 2020
|
15 |
313,036 |
BBIO, Eidos Therapeutics, Inc. (EIDIX), HRMY, SNDX
|
13F-HR
|
11/12/2020 |
000176672120000007 |
|
Q2 2020
|
13 |
262,045 |
BBIO, Eidos Therapeutics, Inc. (EIDIX), AVRO, AGLE
|
13F-HR
|
8/10/2020 |
000176672120000005 |
|
Q1 2020
|
14 |
229,556 |
BBIO, Eidos Therapeutics, Inc. (EIDIX), AVRO, SNDX
|
13F-HR
|
5/11/2020 |
000176672120000003 |
|
Q4 2019
|
13 |
261,004 |
BBIO, Eidos Therapeutics, Inc. (EIDIX), AVRO, AGLE
|
13F-HR
|
2/6/2020 |
000176672120000002 |
|
Q3 2019
|
13 |
191,825 |
BBIO, Eidos Therapeutics, Inc. (EIDIX), AVRO, OBSV
|
13F-HR
|
11/13/2019 |
000176672119000007 |
|
Q2 2019
|
14 |
234,139 |
BBIO, Eidos Therapeutics, Inc. (EIDIX), MRKR, OBSV
|
RESTATEMENT
|
8/13/2019 |
000176672119000005 |
|
Q1 2019
|
12 |
131,269 |
Eidos Therapeutics, Inc. (EIDIX), AVRO, OBSV, Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
|
13F-HR
|
5/20/2019 |
000176672119000003 |
|
Q4 2018
|
12 |
94,914 |
OBSV, Eidos Therapeutics, Inc. (EIDIX), AVRO, MRKR
|
13F-HR
|
2/8/2019 |
000176672119000002 |